VeonGen Therapeutics, a company backed by Canopy Capital, announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase III study and a CMC strategy for VG801, its investigational dual-AAV gene therapy for Stargardt disease and other ABCA4-related retinal dystrophies. This agreement supports the company's preparations for a global pivotal Phase III clinical trial. VG801 first received FDA authorization for a Phase I/II clinical trial in December 2024 and has advanced to the Phase III preparation stage in less than two years. The ongoing Phase I/II study has dosed 15 adult and pediatric patients to date; follow-up data as of October 2026 show sustained improvement across multiple visual function measures, stable retinal structure, and an overall favorable safety profile. VG801 leverages the company's proprietary dual-AAV technology to overcome the delivery limitations of large genes and targets the underlying genetic cause of Stargardt disease. It has received multiple FDA designations and has been selected for the FDA's Rare Disease Endpoint Advancement (RDEA) pilot program. Stargardt disease is a common inherited macular dystrophy that affects a large number of patients worldwide, and no approved therapy currently exists. VeonGen, headquartered in Munich, Germany, is a clinical-stage genetic medicine company with multiple proprietary technology platforms and a pipeline spanning several ophthalmic gene therapies; it is also exploring applications of and collaborations around its related technologies in other therapeutic areas.